AtomVie Global Radiopharma, an Hamilton, ON, Canada-based Contract Development and Manufacturing Organization for the GMP manufacturing and distribution of clinical and commercial radiopharmaceuticals, raised an undisclosed amount in Series A funding.
Avego Management made the investment.
The company intends to use the funds to expand its current clinical GMP manufacturing capacity of radiopharmaceutical products to include commercial stage production through the construction of a new facility designed to accommodate multiple isotopes.
Incorporated in late 2021 and led by CEO Bruno Paquin, AtomVie is a spinout from the CPDC (Centre for Probe Development and Commercialization), and within CPDC, the CMO business unit, now AtomVie, served as the GMP manufacturer and supplier of finished-dose therapeutic radiopharmaceuticals for the past seven years. The company will be expanding its current clinical GMP manufacturing capacity of radiopharmaceutical products to include commercial stage production through the construction of a new purpose-built state of the art facility designed to accommodate multiple isotopes. Moreover, AtomVie complements its manufacturing and logistics expertise with a high-standard quality management system and global regulatory support.
The company has strengthened its operational management with the recent appointment of Dodi Adar, Chief Operating Officer and the promotion of Rezwan Ashique, VP Operations. Ms. Adar brings 17 years of experience in the pharmaceutical industry with expertise in fostering growth and streamlining operational processes. Mr. Ashique was an instrumental part of CPDC’s success for over eight years with more than 20 years of extensive expertise in radiochemistry, development, and GMP manufacturing of ready-to-use radiopharmaceuticals.
FinSMEs
24/08/2022